VENTURE CAPITAL POST

Swiss pharmaceutical group Novartis said on Tuesday the European Commission had approved an additional treatment for its eyecare unit Alcon's Travatan treatment for glaucoma, a chronic, sight-threatening eye disease.

Alcon said in a statement on Tuesday the Travatan eye drops solution had been approved to reduce elevated intraocular pressure in pediatric patients.

"We are pleased to receive the new EU pediatric indication of Travatan, which further strengthens Alcon's globally leading glaucoma portfolio," Jeff George, global head of Alcon, said in a statement.